IL6 and cancer: Furthermore, downregulation of GRP78 by ISL inhibited TGF-β1 secretion from the cancer cells and prevented the activation of CAFs and the inhibition of IL-6, TGF-β1, and MMP-9 by CAFs (Figure 10).